Cargill’s EpiCor postbiotic ingredient health claims licensed by Health Canada
The claims focus on support for immune and digestive health.
Cargill (Minneapolis) announced that Health Canada has licensed 10 health claims for the company’s EpiCor postbiotic ingredient as a Natural Health Product. The health claims focus on support for immune and digestive health.
The claims are based on a daily EpiCor dose of 500 mg in adults aged 18 and older and are backed by more than a dozen published clinical studies, the company says. The claims include:
- Helps to reduce the incidence of cold and flu symptoms (during the winter months)
- Helps to reduce the symptoms of seasonal allergies such as nasal stuffiness/congestion
- Helps relieve nasal stuffiness/congestion associated with seasonal allergies
- Helps to maintain immune function
- An antioxidant that helps to support good health
- Source of antioxidant(s)/provides antioxidant(s)
- Helps support intestinal/gastrointestinal health
- Helps to improve occasional mild to moderate bloating/distension
- Helps to improve occasional mild to moderate feeling of fullness
- Occasionally helps to improve stool consistency
In a press release, Justin Green, PhD, director of scientific affairs for EpiCor, added, “This news, from one of the world’s leading health agencies, affirms the significant body of science behind EpiCor…”
Senate Committee has released the text of 2024 Farm Bill, with changes to hemp regulations
November 19th 2024The U.S. Senate Committee on Agriculture, Nutrition, & Forestry has introduced the Rural Prosperity and Food Security Act, which will serve as the Senate’s draft for the 2024 Farm Bill.
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.
Recent study compares the effectiveness of two probiotic products on colicky infants
October 31st 2024The study compared AB-Biotics and Kaneka Probiotics’ probiotic formulation of Bifidobacterium longum KABP®-042 and Pediococcus pentosaceus KABP®-041 to Lactobacillus reuteri DSM17938 (LR) from Biogaia.
